BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
Wednesday, September 9, 2026
📌TL;DR
Novartis' del-desiran missed the primary endpoint of the Phase 3 HARBOR trial in myotonic dystrophy type 1, roughly 150 patients, with no effect size or p value disclosed, per the September 8 release. NVS American depositary receipts closed down 13.9%, absorbing two Zurich sessions after the US holiday.
Amgen closed down 10.1% at $393.17; press coverage attributed the drop to readacross from pelacarsen's Lp(a) failure to olpasiran plus a BMO Capital downgrade to Market Perform.
The same day, Imdelltra plus Imfinzi met the overall survival primary endpoint of the 563 patient DeLLphi-305 trial as first line maintenance in extensive stage small cell lung cancer; the hazard ratio and medians were withheld for a congress, per Amgen's release.
The FDA granted accelerated approval to AstraZeneca's Etcamah (camizestrant) on Friday, the first cancer approval triggered by a ctDNA resistance mutation before scans show progression, over an advisory committee vote reported as 6 to 3 against in April.
Boston Scientific told the SEC it is unlikely to meet third quarter and full year 2026 guidance and that the cyberattack's impact will be material; revised numbers come October 28. BSX closed down 5.9%.
BrainChild Bio closed a $116M Series A for pediatric brain tumor CAR T therapy and a pivotal DIPG trial, and Moonwalk Biosciences raised a $70M Series B for an siRNA obesity candidate, per both companies' releases.
⚡ Executive Takeaway
We set the surrogate discount frame yesterday morning. By the close, the market had run it in size, and it picked the wrong pocket first. Amgen lost a tenth of its value on the failure of a trial it is not running, in a molecule it does not own, in a modality it does not use. That is the surrogate discount stopping being a framework and becoming a price.
What the tape did not do is discriminate. It sold the class question and paid nothing for the asset level facts: not for olpasiran's deeper Lp(a) lowering, not for the valuation logic BMO actually cited, and not for a statistically significant survival win Amgen printed the same morning. Readacross selling is blunt by construction, because the only new information was about a target, not about any specific program. The sharp information arrives when Novartis presents the pelacarsen data, on a date Novartis has not set. Until then, day one moves like today's price the worst case, and the discipline is knowing that is what they do. The Pro brief takes apart who actually owes what. 👉 Read Full Analysis
🧪 Pharma
Novartis' $12 billion Avidity bet failed its first Phase 3, and the number stayed home. NVS
Del-desiran (delpacibart etedesiran), the lead asset from the $12 billion Avidity Biosciences acquisition, missed the primary endpoint of the roughly 150 patient HARBOR trial in myotonic dystrophy type 1, showing no statistically significant improvement over placebo on video hand opening time. Novartis disclosed no effect size and said full data will go to health authority discussions and a future congress, while claiming numberless evidence of clinical activity on secondaries. It is the company's third setback in a week after the rap-cel pause and pelacarsen, and the third Novartis miss announced without its numbers. Barclays had modeled $3.1 billion in peak sales at 60% odds, per Reuters. NVS ADRs closed down 13.9%; Zurich shares fell roughly 9%, which CNBC reported was tracking toward the stock's worst day on record.
📉 The Tape
Amgen lost a tenth of its value over a trial it is not running. AMGN
Amgen closed at $393.17, down 10.1%, with no new Amgen data behind the move. Coverage attributed the selloff to pelacarsen readacross against olpasiran, Amgen's Lp(a) lowering siRNA whose OCEAN(a) outcomes trial is ongoing, plus a BMO Capital downgrade from Outperform to Market Perform that kept a $450 target and cited the roughly 34% year to date run and coming losses of exclusivity, per Yahoo Finance. Note the two reasons are different claims: one is about the science, one is about the price. Amgen made no statement on olpasiran within the scope of our sweep, and no new Lp(a) data exist anywhere; the class question stays open until the pelacarsen congress print.
🎗️ Oncology
Imdelltra won first line small cell lung cancer maintenance, and nobody paid for it. AMGN | AZN
Amgen's Imdelltra (tarlatamab-dlle) plus AstraZeneca's Imfinzi met the overall survival primary endpoint of DeLLphi-305 at a planned interim analysis, in 563 patients with extensive stage small cell lung cancer who had not progressed after first line Imfinzi, platinum chemotherapy and etoposide. Progression free survival and response rate secondaries were also met, safety was consistent with known profiles, and every number was withheld for an unnamed congress. This is the withheld number after a win we wrote about Friday, a second catalyst nobody has been charged for, and today it came free with a 10.1% discount attached.
🧬 Regulatory
The FDA approved a breast cancer drug its own advisers voted down, on a blood test trigger. AZN
The FDA granted accelerated approval to Etcamah (camizestrant) on Friday for HR positive, HER2 negative advanced breast cancer upon detection of an emergent ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, with Guardant360 CDx authorized as the companion test. It is, per the FDA's own oncology leadership, the first cancer approval guided by a resistance mutation found in circulating tumor DNA before imaging shows progression. SERENA-6 cut progression risk 56%, with median PFS of 16.0 versus 9.2 months, and the advisory committee still voted against it in April, reported as 6 to 3, on doubts about the switch early design. Third contested review reversal in two months, after Replimune and uniQure. Leerink calls the approved use modest, about $750 million, with $2.9 billion possible if SERENA-4 hits in the second half.
💰 Capital Markets
Two private rounds raised $186 million into the ugliest tape of the month.
BrainChild Bio closed a $116 million Series A to take CAR T cell therapy for pediatric brain tumors into a pivotal trial in diffuse intrinsic pontine glioma, and Moonwalk Biosciences raised a $70 million Series B, with Eli Lilly and ARCH Venture Partners among the investors, for MW101, a small interfering RNA aimed at adipose tissue in obesity, first in human late 2027. The cell therapy read: ex vivo CAR T still finances readily in oncology while the autoimmune side of the field sits in a safety pause with no primary document. The RNAi read: the modality raised new obesity money the same week an oligonucleotide class thesis got contradicted, because the wager here is tissue biology, not a surrogate.
🩺 Medtech
Boston Scientific's 8-K arrived, material and numberless. BSX
The company filed the cybersecurity 8-K we have been waiting for, saying it is unlikely to meet third quarter and full year 2026 sales and adjusted EPS guidance issued July 29 and that the incident's impact on results will be material, while attaching no figures; revised guidance comes with earnings on October 28. Operations are mostly back: distribution substantially restored, sterilization fully operational, manufacturing resumed across most facilities, no timeline for full recovery. J.P. Morgan, per MedTech Dive, flags that a disposables heavy mix recaptures less lost revenue than capital equipment did for Stryker after its March attack. BSX closed down 5.9%. Separately, MedTech Dive reported NovoCure disclosed a mid August breach exposing more than 1,400 patient records.
📋 Quick Hits
Spyre Therapeutics' anti IL-23 antibody SPY003 met the induction primary endpoint in the Phase 2 SKYLINE ulcerative colitis trial, per its September 8 release, completing proof of concept for all three antibodies in its planned IBD combinations. SYRE
Roivant's Pulmovant presented positive Phase 2 PHocus data for mosliciguat, its inhaled sGC activator licensed from Bayer, in pulmonary hypertension associated with interstitial lung disease at ERS, with the Phase 3 PHrontier study already running. ROIV
Abbott won FDA approval for the TactiFlex Duo ablation catheter, delivering both pulsed field and radiofrequency energy for atrial fibrillation. ABT
Sandoz laid out a biosimilars buildout running to 2040, calling the coming patent cliff a golden decade, per Fierce Pharma; and BioSpace looked at how Moderna and Merck's individualized mRNA cancer vaccine win shifts manufacturing toward scaling out, not up.
Amylyx logged a seventh straight close below its $35.50 offer price with the offering's closing still unannounced as of Tuesday night's check; the greenshoe forces disclosure by about September 18. Lilly's Sangamo platform purchase also remains unconfirmed as closed. AMLX
📖 In Today's Full Analysis
Be sure to read the full article for all the details, including:
The full SERENA-6 data table and Etcamah's road through a reported 6 to 3 no vote
The withheld number ledger: four readouts in five days announced without their figures, and when each comes due
DeLLphi-305's design, and what first line maintenance would change for small cell lung cancer
The full September 8 market close table, eleven tickers, official exchange closes
🔒 BioMed Nexus Pro
In Today's Pro Brief...
🧠 The readacross bill: why the bystander with the biggest offset paid the most today, and the one number that decides whether the selling was right
💊 The agency that just discounted a surrogate approved one four days later; what resolves the contradiction, and what it says about the next contested review
📊 Two withheld numbers, two prices: one is a debt, one is a free option, and the market just mispriced the option in your favor
🎯 Plus the week's coming catalysts, with the full calendar returning Friday
The frame we set yesterday traded its first full session today, and it picked the bystander's pocket. Two more sessions until the Friday tally. What are you watching? Reply to this email.
Sponsorship slots for 2026 are limited. See packages and pricing →
NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →